Barry Reiner
Pediatric Endocrinology · Baltimore, MDNPI 1386738938
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 19.2%. Among pediatric endocrinology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $45.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$3K
- Merck$2K
- Tandem Diabetes Care, Inc.$2K
- Novo Nordisk$2K
- Eli Lilly$1K
- AbbVie$495
- plus $4K from 32 others
Across 2,425 payments — averaging $863.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$893K
- Novo Nordisk AS$706K
- Medtronic$367K
- Merck$75K
- Mannkind Corporation$37K
- Daiichi Sankyo Inc.$14K
- plus $3K from 1 others
What the payments were for
- Speaking & faculty fees$4,12528%
- Travel & lodging$2,74518%
- Food & beverage$7,74952%
- Education$2051%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 29 | $2,854 |
| Merck | 15 | $2,234 |
| Tandem Diabetes Care, Inc. | 15 | $2,175 |
| Novo Nordisk | 75 | $1,646 |
| Eli Lilly | 7 | $1,481 |
| AbbVie | 21 | $495 |
| Insulet Corporation | 9 | $367 |
| Ascendis Pharma Endocrinology Inc | 11 | $300 |
| Tolmar, Inc. | 11 | $288 |
| Rhythm Pharmaceuticals, Inc. | 10 | $280 |
| Sanofi-aventis U.S. LLC | 12 | $273 |
| Dexcom, Inc. | 15 | $242 |
| Pfizer | 10 | $214 |
| Xeris Pharmaceuticals, Inc. | 10 | $212 |
| BETA Bionics, Inc. | 5 | $198 |
| Medtronic(2 entities) | 8 | $183 |
| Neurocrine Biosciences, Inc. | 6 | $170 |
| Amneal Pharmaceuticals LLC | 7 | $143 |
| Lifescan, Inc. | 5 | $119 |
| Abbott | 5 | $101 |
| Lilly USA, LLC | 5 | $100 |
| Amphastar Pharmaceuticals, Inc. | 4 | $94 |
| Azurity Pharmaceuticals, Inc. | 3 | $83 |
| IBSA Pharma Inc. | 3 | $77 |
| Arbor Pharmaceuticals, Inc. | 4 | $73 |
| Companion Medical, Inc. | 2 | $72 |
| Tolmar Pharmaceuticals, Inc. | 3 | $66 |
| AstraZeneca | 2 | $51 |
| Kyowa Kirin, Inc. | 2 | $44 |
| BD | 2 | $39 |
| Eton Pharmaceuticals, Inc. | 1 | $34 |
| Zealand Pharma US, Inc. | 1 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $29 |
| Sandoz | 1 | $28 |
| Intuity Medical Inc | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $20 |
| RGH Enterprises LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$2,230
- STEGLATRO$1,788
- t-slim insulin pump$1,500
- HUMALOG$1,346
- t:slim X2 insulin pump$500
- DEXCOM G6 TRANSMITTER$112
- Omnipod$102
How this compares
$14,884 in reported general payments places this provider in the 95th percentile of 33 pediatric endocrinology providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OmnitropeSomatropin | 11 | $27,510 |
| Levothyroxine Sodium | 26 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $143 | $19126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 pediatric endocrinology providers in Maryland.
Other pediatric endocrinology in Baltimore
- David CookeBaltimore$8K
- Risa WolfBaltimore$7K
- Ryan MillerBaltimore$5K
- Sandra SalsbergBaltimore$3K
- Katherine BeckwithBaltimore$871
- Paula NewtonBaltimore$854
- Talia HittBaltimore$350
- Albara MarwaBaltimore$178
- Scott BlackmanBaltimore$156
- Joseph HeinemannBaltimore$147
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.